Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.

Published in: PLoS medicine (2024)

In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.

Keyphrases

rheumatoid arthritis
public health
healthcare
traumatic brain injury
drug induced
mental health
health information
adverse drug
emergency department